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Introduction: Large cell neuroendocrine carcinoma (LCNEC) is a rare and highly
aggressive high-grade neuroendocrine neoplasm, which can arise from anywhere in the
body. Due to its rarity there is a lacuna in our understanding of LCNEC’s molecular
biology. In 2016, Rekhtman and colleagues presented one of the largest molecular
sequencing series of pulmonary LCNEC. They differentiated genomic profiles of LCNEC
into two major subsets: small cell lung cancer (SCLC)-like, characterized by TP53 + RB1
co-mutation/loss, and non-small cell lung cancer (NSCLC)-like, characterized by the lack
of co-altered TP53 + RB1. This finding is of significance because at present LCNEC
patients are often treated like SCLC. However, the universal genomic SCLC biomarker of
TP53 and RB1 co-mutation was only found in 40% of their cohort. Since then various
other scientists have looked into molecular profiling of LCNEC with markedly discordant
results. The objective of this study was to conduct a systematic review of publicly available
next generation sequencing (NGS) data to evaluate the prevalence of TP53 + RB1 co-
mutation in LCNEC.
Method: We conducted a literature search using PubMed. Seven studies including 302
patients with pulmonary LCNEC and four studies including 20 patients with extra-
pulmonary LCNEC underwent final analysis.
Results: The prevalence of TP53 + RB1 co-mutation was 36% (109/302) among
pulmonary LCNEC patients and 35% (7/20) among the extra-thoracic LCNEC cohort.
This finding is in stark contrast to >90% TP53 + RB1 co-mutation in SCLC.
Conclusion: It is now well established that LCNEC is molecularly distinct from SCLC.
LCNEC seems to have two molecularly defined sub-cohort based on TP53 + RB1 co-
mutation status. Future studies should look into prognostic and predictive implication of
TP53 + RB1 co-mutation status in LCNEC. Prospective studies should be designed to
characterize molecular subtypes and direct treatment accordingly. We are currently
conducting a prospective pilot clinical trial wherein LCNEC patients are treated based
on TP53 + RB1 co-mutation status. The study is currently enrolling. “Next Generation
Sequencing-Based Stratification of Front Line Treatment of Neuroendocrine Carcinoma
(PRECISION-NEC).
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INTRODUCTION
Large cell neuroendocrine carcinoma (LCNEC) is a rare and highly
aggressive high-grade neuroendocrine neoplasm which can arise
from anywhere in the body. Due to the rarity of LCNEC there has
been a lacuna in our understanding of LCNEC’s molecular biology.
Current research efforts largely focus on the identification of unique
molecular profiles associated with pulmonary LCNEC (1–8).
Numerous challenges have been encountered in attempts to
molecularly characterize pure pulmonary LCNEC. Some of the
reasons may be due to the morphologic similarity of pulmonary
LCNEC compared to other pulmonary neuroendocrine carcinomas,
the rapidly changing classification and diagnostic criteria, and
LCNEC combined with any of the various subtypes (9, 10). The
difficulty of this endeavor is demonstrated in several studies inwhich
pathologists have reclassified a patient’s lung cancer diagnosis
following a central review, exclusion of patient tumor sample as a
result of notmeeting pulmonary LCNECdiagnostic criteria set forth
in the protocol, or requiring a panel-consensus for clinical diagnosis
required for study inclusion (2–4, 7, 11–14).
Shortly after the recognized classification of pulmonary
LCNEC, researchers utilizing immunohistochemistry reported
that pulmonary LCNEC samples could be characterized by high
Ki-67 indices with loss of TP53 and RB1 activity (15–18). Although
pulmonary LCNEC had been classified as a subset of NSCLC,
immunohistochemistry studies found that pulmonary LCNEC was
genetically and immunohistochemically similar to small cell lung
cancer (SCLC) (19). Then the list of genes interrogated were
expanded to aid in the identification of genomic abnormalities
that may differentiate LCNEC from other large cell subtypes, as
well as identify any prognostically significant or potentially
actionable alterations in an attempt to improve outcomes.
With the interrogation of a limited number of genes and large
degree of heterogeneity among published studies, researchers
utilized modern techniques (next generation sequencing or NGS
and whole exome sequencing or WES) to characterize the
diagnosis, prognostication, and treatment of pulmonary
LCNEC. In 2013, the Clinical Lung Cancer Genome Project
and Network Genomic Medicine submitted 15 pulmonary
LCNEC samples for WES. All but one sample demonstrated a
TP53 or RB1 mutation or loss with 20% (n = 3) samples
harboring an EP300 mutation. The genomic profile largely
overlapped with alterations reported in SCLC samples and,
thus, unsurprisingly the probability of survival of LCNEC
patients mirrored that seen in SCLC patients (6).
Rekhtman and colleagues presented the largest breakthrough
regarding the classification of pulmonary LCNEC utilizing
genomic data (3). Following surgical resection, a central
pathology group reviewed biopsies to include only pure
LCNEC that met WHO 2015 criteria which were then
submitted for paired tumor/normal NGS analysis of all exons
and selected introns of 241 genes (n = 45). TP53 (n = 35, 78%)
and RB1 (n = 17, 38%) were the two most commonly altered
genes observed in previous studies (2, 6). As a result of a recent
NGS study of SCLC which demonstrated that concomitant
inactivation of RB1 and TP53 is a defining feature of SCLC
(20), Rekhtman and colleagues categorized samples harboring
co-inactivation of RB1 and TP53 as SCLC-like (n = 18, 40%) and
classified samples that did not harbor co-inactivation of RB1 and
TP53 as NSCLC-like (n = 25, 68%) (3).
Since then various other studies listed above demonstrate the
heterogeneity of pulmonary LCNEC with markedly discordant
results with the Rekhtman and colleagues study suggesting the
ability to sub-classify pulmonary LCNEC based upon the observed
genomic alterations (2, 3, 6–8). The objective of this study was to
conduct a systematic review of publicly available NGS data to
evaluate the prevalence of TP53 + RB1 co-mutation in LCNEC.
METHODS
We aimed to identify all available NGS data to evaluate the
prevalence of TP53 + RB1 co-mutation in LCNEC. We
conducted a literature search of PubMed through the
University of Kentucky library portal. Manuscripts were
excluded if molecular profiling was not performed by NGS,
full-length manuscripts were not available, manuscripts were in
a language other than English or did not pertain to humans.
Duplicate publications were also excluded. Using PRISMA
guidelines, data was extracted from manuscripts and
supplementary publication if available. Following search terms
were used to find LCNEC related NGS publications in PubMed:
1. Large cell neuroendocrine carcinoma AND genetics: Search
Results ! Items: 507
2. Large cell neuroendocrine carcinoma AND gene expression:
Search Results ! Items: 247
3. Large cell neuroendocrine carcinoma AND next generation
sequencing: Search Results ! Items: 45
4. (“Neuroendocrine Tumors”[Mesh] AND “Carcinoma, Large
Cell/genetics”[Mesh]) OR (“Carcinoma, Neuroendocrine/
genetics”[Mesh] AND “Carcinoma, Large Cell”[Mesh]):
Search Results ! Items: 7
RESULTS
The literature search identified 878 LCNEC studies out of which
824 were full text articles. After exclusion of non-human and
non-English studies, 726 records were identified. These studies
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were then screened for duplicates. After removal of duplicate
records, 461 studies were assessed for eligibility. Studies not
meeting NGS molecular profiling were further excluded.
Moreover, duplicate data sets used by multiple investigators
were excluded. Altogether, 11 studies, including seven
pulmonary LCNEC containing 302 patients and four extra-
thoracic studies including 20 patients, underwent final analysis.
Out of four extra-thoracic LCNEC studies, two were pancreatic
LCNEC and two were colorectal LCNEC. Figure 1 illustrates the
flow diagram of the search process and Table 1 lists pulmonary
LCNEC studies that were analyzed for the presence of TP53 and
RB1 mutation. According to our systematic report, in the
pulmonary LCNEC cohort the prevalence of genetic alterations
in TP53 was 64 to 93% and genetic alterations in RB1 was 27 to
100%. The prevalence of TP53 + RB1 co-mutation in pulmonary
LCNEC ranged from 18 to 93% across the individual studies.
Together, 36% (109/302) of pulmonary LCNEC patients revealed
the presence of TP53+RB1 co-mutation. Similarly, Table 2 lists
extra-thoracic LCNEC studies that were analyzed for the
presence of TP53 and RB1 mutation. According to our review,
the prevalence of genetic alterations in TP53 is 67 to 100% and
the genetic alterations in RB1 was 22 to 100%. The prevalence of
TP53 + RB1 co-mutation in non-pulmonary LCNEC ranged
from 11 to 100% across the individual studies. When combined,
35% (7/20) of extra-thoracic LCNEC patients revealed the
presence of TP53 + RB1 co-mutation.
FIGURE 1 | Flow Diagram of Search Results for LCNEC.












68 55 (81%) 20 (29%) 12 (18%)
Rekhtman
et al. (3)
45 35 (78%) 17 (38%) 18 (40%)
Derks et al.
(4)
79 67 (85%) 37 (47%) 34 (43%)
George et al.
(21)
60 55 (92%) 25 (42%) 24 (40%)
Ito et al. (22) 22 14 (64%) 6 (27%) 4 (18%)
Karlsson
et al. (23)
14 13 (93%) 14 (100%) 13 (93%)
Zhou et al.
(24)
14 12 (86%) 5 (36%) 4 (29%)
All Studies 302 251 (83%) 124 (41%) 109 (36%)
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DISCUSSION
LCNEC is a rare and highly aggressive high-grade neuroendocrine
neoplasm with poorly understood molecular biology. Current
research efforts largely focus on identification of a unique
molecular profile of this tumor type in hopes of stratifying
different subtypes, establish and optimize therapeutic regimen,
and reveal novel therapeutics targets.
In 2016, Rekhtman and colleagues (3) differentiated genomic
profiles of LCNEC into two major subsets: SCLC-like, characterized
by TP53 + RB1 co-mutation/loss, and NSCLC-like, characterized by
the lack of co-altered TP53 + RB1. This is considered a major
breakthrough regarding the classification of pulmonary LCNEC
utilizing genomic data and is of great significance because at present
all LCNEC patients are treated like SCLC. However, the universal
genomic biomarker of TP53 and RB1 co-mutation was only found
in 40% in their cohort.
Similarly, genomic analysis of 60 LCNECs by George and
colleagues (21) identified two molecular subgroups: type I
LCNECs defined as bi-allelic TP53 and STK11/KEAP1 alterations
(37%), and type II LCNECs enriched for bi-allelic inactivation of
TP53 and RB1 (42%). Another study by Miyoshi and colleagues (2)
found relatively high frequency of TP53 and RB1 mutation in their
LCNEC cohort, which suggested the similarity of LCNEC to SCLC.
After conducting a systematic review of publicly available
NGS data to evaluate the prevalence of TP53 + RB1 co-mutation
in LCNEC and combining these studies, we found similar trends,
with a prevalence of 36% (109/302) TP53 + RB1 co-mutation in
pulmonary LCNEC and 35% (7/20) TP53 + RB1 co-mutation in
of extra-thoracic LCNEC patients. Our systematic review reveals
a stark contrast to >90% TP53 + RB1 Co-mutation in SCLC (29,
30). This is of great importance because currently, many centers
treat LCNECs like SCLC with platinum doublet regimen
(Cisplatin/Carboplatin-Etoposide). However, we believe not all
LCNECs should be treated the same. The distinct molecular
identity of LCNEC as compared to SCLC warrants LCNEC-
specific management strategies.
CONCLUSIONS
LCNEC is a molecularly heterogeneous cancer and most studies
confirm the presence of two distinct subpopulations: SCLC-like,
characterized by TP53 + RB1 co-mutation/loss, and NSCLC-like,
characterized by the lack of co-altered TP53 + RB1. Our
understanding of molecular biology of LCNEC should lead us to
evaluate LCNEC-specific treatment regimens rather than
extrapolating data from SCLC studies. Due to the low frequency at
which LCNEC is diagnosed and the difficulty in obtaining pure
LCNEC study populations, prospective clinical trials evaluating the
optimal chemotherapy regimen are lacking. Large, multi-center,
prospective studies are warranted to confirm whether different
genomic subtypes of LCNEC require different treatment modalities
and to establish an optimal regimen for each subtype. Future studies
should look into prognostic and predictive implication of TP53 + RB1
co-mutation status in LCNEC. Prospective studies should be designed
to characterize molecular subtypes and direct treatment accordingly.
We are currently conducting a prospective pilot clinical trial wherein
LCNECpatients are treated based on TP53 +RB1 co-mutation status.
The study is currently enrolling. “Next Generation Sequencing-Based
Stratification of Front Line Treatment of Neuroendocrine Carcinoma
(PRECISION-NEC). ClinicalTrials.gov Identifier: NCT04452292”.
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